Clinical Trials Directory

Trials / Completed

CompletedNCT01570907

Crossover Bioequivalence Study of Quetiapine Fumarate 25 mg Tablets Under Fasted Conditions

A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Quetiapine Fumarate 25 mg Tablets Under Fasting Conditions

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Roxane Laboratories · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The objective of this study was to prove the bioequivalence of Roxane Laboratories' Quetiapine Fumarate 25 mg Tablet under fasted conditions.

Conditions

Interventions

TypeNameDescription
DRUGQuetiapine Fumarate25 mg tablet

Timeline

Start date
2007-06-01
Primary completion
2007-07-01
Completion
2007-07-01
First posted
2012-04-04
Last updated
2018-01-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01570907. Inclusion in this directory is not an endorsement.